6 complementary overhangs containing individual PRRSV antigenic epitope sequences ( Table 1) . 116 A second round of fusion PCR was performed to assemble the previously synthesized amplicons. 117
The PCR product was digested with KpnI and inserted into the pCR2.1TOPO vector (Invitrogen) 118 (Fig. 1) . Recombinant plasmids containing the insert were transformed into the alpha-select 119 strain of E. coli (Bioline). Positive clones were selected, and insertion of each specific PRRSV 120 epitope was confirmed by DNA sequencing. The viral genomic DNA was excised from the 121 plasmid by enzymatic digestion with KpnI and concatemerization was carried out through a 122 ligation reaction with T4 DNA ligase (Invitrogen), overnight, at room temperature. The 123 infectious chimeric virus was generated by transfection of the concatemerized genomic DNA 124 into the PCV1-free PK15 cells at 30%-40% confluency with lipofectamine ltx (Invitrogen) . 125
After 72 h post-transfection, the infectious virus was harvested by three cycles of freezing and 126 thawing of the cells. 127 128
In vitro infectivity, epitope expression, and titration of chimeric PCV1-PRRSV EPI 129
viruses: 130 PCV1-free PK-15 cells were seeded at a concentration of 2 × 10 5 cells/well in a 48-well 131 plate. After reaching approximately 40%-50% confluency, cells were washed once with Hank's 132
Balanced Salt Solution (Gibco). The cells were then incubated with 100 µL of 1:10 serial 133 dilution of the virus stock for 1 h at 37°C in 5% CO 2 , after which the cells were washed once 134 with 200 µL of minimum essential media (MEM) (Gibco). Infection was carried out in 300 µL 135 MEM supplemented with 10% FBS (Invitrogen) and 1% antibiotic/antimycotic (Fisher) at 37°C 136 in 5% CO 2 . After 72 h post-infection, the cells were fixed with 80% acetone and the infectivity 137
was assessed by an immunofluorescence assay (IFA).
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Briefly, infected cells were incubated with 100 µL of mouse anti-PCV1-Cap monoclonal 139 antibody, followed by fluorescein isothiocyanate-conjugated goat anti-mouse IgG (KPL, 140 Kirkegaard & Perry Laboratories, Inc.). Expression of PRRSV-specific antigenic epitopes was 141 also confirmed by IFA using custom polyclonal rabbit antibodies (Biomatik) against each 142 synthetic PRRSV epitope followed by secondary goat anti-rabbit IgG (DyLight 550). Cells 143 positive for both PCV1 Cap and PRRSV epitopes were visualized using a Zeiss LSM 880 144 confocal microscope (Zeiss, Pleasanton, CA). Serial ten-fold dilutions of the virus stock were 145 performed in order to determine the 50% tissue culture infectious dose (TCID 50 ) of the virus 146 stocks according to the method described by of Reed and Muench (Reed and Muench, 1938) . 147 148
In vivo characterization of the infectivity and immunogenicity of four PCV1-149

PRRSV EPI chimeric viruses 150
Experimental design for the animal study 151
A total of 21 5-weeks-old specific-pathogen-free (SPF) pigs were randomly assigned into 152 seven groups of three pigs each, including two positive control groups (PCV1 and PRRSV), a 153 negative control (MEM-treated group), and four groups for each of the PCV1-PRRSV EPI 154 chimeric viruses. Pigs in each of the PCV1-PRRSV EPI chimeric virus groups and the PCV1-155 positive control group were intramuscularly inoculated with 5 mL (4.64 × 10 2 TCDI 50 /mL) of the 156 respective viruses. Pigs in the PRRSV-VR2385-positive control group were each inoculated 157 with 5 mL (2 × 10 5 TCDI 50 /mL) of PRRSV-VR2385. Serum samples were collected from each 158 pig prior to inoculation and weekly thereafter for a period of 7 weeks. 159 160 8
Quantification of viral DNA loads in sera and lung tissues 161
The viral DNA was extracted from serum samples at 0, 7, 14, 21, 28, 35 , and 42 days 162 post-inoculation (dpi) and from tissues (lung and tracheobronchial lymph node) at 42 dpi, using 163 Ambion MagMAX-96 Viral DNA Isolation kit (Thermo Fisher Scientific) according to the 164 manufacturer's instructions. The DNA standards used for the qPCR were virus stock used for 165 inoculation as well as plasmids containing the full-length PCV1 infectious clone. In order to rule 166 out potential cross-contamination, DNA extracted from PCV2a and PCV2b virus stocks, and 167 empty pCR2.1TOPO vector (Invitrogen), were included as the negative control. The PCV1 DNA 168 copy numbers in sera or tissues were quantified by a TaqMan ® Fast Virus 1-Step Master Mix 169 (Life Technologies Corp.) according to the manufacturer's protocol. The PCR primers and 170 probes (PCV1 P9/PCV1 P10/PCV1 probe) ( Table 1 ) used in the qPCR assay were designed to 171 target a specific amplicon of 97 bp in ORF2. The qPCR assay was conducted using the ABI 7500 172 The neutralizing antibody titers against PRRSV-VR2385 were determined by a serum 214 virus neutralization assay essentially as previously described (Zhou et al., 2012) . Briefly, two-215 fold diluted serum samples collected at 28, 35, and 42 dpi from each pig were mixed with an 216 equal volume of the PRRSV VR2385 virus at an infectious titer of 2 × 10 3 TCID 50 /mL and 217 incubated at 37°C for 1 h. The mixtures were then inoculated onto MARC-145 cells in 96-well 218 plates and incubated for 1 h at 37°C. After washing with PBS, the cells were maintained in 219 DMEM with 2% FBS. At approximately 20 hpi, the cells were assayed by IFA for virus 220 infection. The neutralizing antibody titers were expressed as the highest dilution that showed a 221 90% or above reduction in the number of fluorescent foci compared to that of antisera from 222 negative control pigs. Samples were evaluated in triplicate and three independent tests were 223 performed for each serum sample. 224 225
Statistical analysis 226
The Student's t-test (unpaired) was used to evaluate the differences (P <0.05) between the 227 samples in the two groups. Repeated measure two-way ANOVA with Tukey's correction was 228 calculated for multiple comparison. Statistical significance was set to alpha = 0.05. All analyses 229 11 were performed using commercially available software GraphPad Prism® 6 (GraphPad 230 Software, Inc, CA). 231 PRRSV antigenic determinant (Fig. 2) . Infected cells showed dual nuclear staining with both 241 anti-PCV1 monoclonal antibodies and anti-PRRSV epitope peptides (GP2 II, GP3I, GP5I, and 242 GP5IV) mono-specific antibodies. There was no significant difference in the genomic copy 243 numbers between wild-type PCV1 and PCV1-PRRS EPI chimeric viruses at 96 hpi (data not 244 shown). The stability of chimeric viruses was confirmed after five successful serial passages in 245 PK-15 followed by dual IFA staining of the PCV1 capsid and respective PRRSV antigenic 246 determinant, as well as by sequence confirmation of the chimeric viruses harvested after the five 247 passages (data not shown). 248
PCV1-VR2385 EPI chimeric viruses are viremic and replicate in tissues of 249 experimentally inoculated pigs: 250
All serum samples, evaluated by TaqMan® qPCR for the presence of PCV1 prior to 251 inoculation at day 0, were negative. Viremia was detected at as early as 7 dpi for PCV112 VR2385 EPI GP3I and PCV1-VR2385 EPI GP5IV viruses, and at 21 dpi for PCV1-VR2385 EPI GP2II 253 and PCV1-VR2385 EPI GP5I viruses ( Table 2 ). The frequency of pigs showing viremia in each 254 group varied during the trial. The number of animals used and the frequency variability do not 255 allow for robust statistical analysis; however, the average DNA viral loads in serum samples 256 from each chimeric virus were within one log 10 difference: 1.39 × 10 5 genomic copies/mL for 257 PCV1-VR2385 EPI GP2II; 1.87 × 10 5 genomic copies/mL for PCV1-VR2385 EPI GP3I; 4.22 × 10 5 258 genomic copies/mL for PCV1-VR2385 EPI GP5I; and 1.96 × 10 5 genomic copies/mL for PCV1-259 VR2385 EPI GP5IV, and had at least two-log 10 lower genomic copies/mL than the parental PCV1 260
(1.26 × 10 7 genomic copies/mL) (Fig. 3A) . After 42 dpi, all animals were necropsied and no 261 significant pathological lesions were observed. However, all infected groups had detectable viral 262 DNA in the tracheobronchial lymph nodes and lungs (Table 2) antibodies were detected from 14 dpi in wild-type PCV1-infected pigs and remained seropositive 273 at 42 dpi. Anti-PCV1 IgG antibodies were detected in PCV1-VR2385 EPI GP3I-and PCV1-274 VR2385 EPI GP5IV-infected groups at 14, 21, and 28 dpi, followed by a significant titer reduction 275 13 compared to the wild-type PCV1 at 35 and 42 dpi. The remaining chimeric viruses-infected 276 groups, PCV1-VR2385 EPI GP2II and PCV1-VR2385 EPI GP5I, showed a delayed seroconversion to 277 anti-PCV1 IgG antibodies (35 dpi) and significantly lower levels of anti-PCV1 IgG antibodies, 278 compared to the wild-type PCV1-infected group, at 35 and 42 dpi (Fig. 4A) . Anti-PCV1 IgG 279 antibodies were not detected in PRRSV or MEM control groups. As expected, anti-PRRSV N 280 antibodies were only detected in the PRRSV 2385 infected group (Fig. 4B) . 281
Antibody responses against the inserted PRRSV antigenic epitopes were detected by 282 specific epitope-based ELISA. Antibody response against PRRSV-GP2 epitope II was not 283 detected in pigs experimentally infected with the PCV1-VR2385 EPI GP2II chimeric virus (Fig.  284 5A). However, specific antibodies against PRRSV-GP3 epitope I were detected in the PCV1-285 VR2385 EPI GP3I chimeric virus group at 28 dpi and remained positive at 42 dpi (Fig. 5B) . 286
Specific antibodies against PRRSV-GP5 epitope I were detected at 21 dpi in the wild-type 287 PRRSV VR2385-infected group, and at 35 dpi in the PCV1-VR2385 EPI GP5I chimeric virus-288 infected group at 35 dpi, and remained positive at 42 dpi (Fig. 5C) . The presence of anti-289 PRRSV-GP5 epitope IV antibodies was detected at 21 dpi in the PCV1-VR2385 EPI GP5IV 290 chimeric virus group and at 28 dpi in wild-type PRRSV VR2385 group, and remained at a high 291 level in the PCV1-VR2385 EPI GP5IV chimeric virus group at 35 and 42 dpi (Fig. 5D) . The low 292 number of animals per group, as well as individual variation amongst animals may play a role in 293 the different levels of antibodies response observed amongst groups. 294 295
PCV1-PRRSV EPI chimeric viruses-infected pigs develop neutralizing antibodies 296 against the PRRSV VR2385: 297
To investigate whether PCV1-VR2385 EPI chimeric viruses can induce neutralizing 298 antibodies against PRRSV, a serum virus neutralization assay against PRRSV VR2385 strain 299 was performed. Anti-PRRSV-VR2385 neutralizing antibodies were detected in the PCV1-300 VR2385 EPI GP3I, PCV1-VR2385 EPI GP5I, and PCV1-VR2385 EPI GP5IV chimeric viruses-infected 301 groups at 28 dpi and remained detectable at 42 dpi. No statistical difference in neutralizing 302 antibody titers were observed throughout the experiment between wild-type PRRSV VR2385 303 and PCV1-VR2385 EPI GP3I, PCV1-VR2385 EPI GP5I, and PCV1-VR2385 EPI GP5IV, except for 304 PCV1-VR2385 EPI GP5I at 42 dpi (Fig. 6) . PRRSV 2385 neutralizing antibodies were not detected 305 in PCV1 or MEM control groups. 306 307
Discussion 308
PCV1 is a non-pathogenic virus in pigs infecting multiple tissues and organs (Allan et al., 309 1995; Calsamiglia et al., 2002; Krakowka et al., 2000) . Early field studies reported a high 310 serological prevalence of anti-PCV1 antibodies in the swine population (Dulac and Afshar, 1989; 311 Edwards and Sands, 1994; Tischer et al., 1995) , although no disease could be associated with the 312 presence of this virus either naturally or experimentally (Allan et al., 1995; Tischer et al., 1986) . 313 However, more recent field studies have demonstrated that the serological prevalence of anti-314 PCV1 antibodies as well as virus circulation in the swine population are very low (Puvanendiran 315 et al., 2011) . Sequence and phylogenetic analyses have also demonstrated a low mutation rate 316 and low genetic diversity of the PCV1 strains worldwide (Tombácz et al., 2014) . Thus, the low 317 prevalence of PCV1, lack of evidence of pathogenicity, low mutation rate, and systemic tropisms 318 15 for multiple tissues and organs make PCV1 an attractive candidate for a potential live vaccine 319 vector. 320
Previous studies have successfully used the non-pathogenic PCV1 as the genomic 321 backbone for the development of PCV2 vaccines (Fenaux et al., 2004) . Cloning of PCV2 ORF2 322 capsid gene into the backbone of PCV1 proved to be viable in vivo and conferred full protection 323 against PCV2, whilst still retaining the non-pathogenic nature of PCV1 (Fenaux et al., 2004; 324 Fenaux et al., 2003) . Additionally, pigs experimentally infected with a PCV2-1 reciprocal 325 chimeric virus, containing PCV1 ORF2 in a PCV2 backbone, showed specific anti-PCV1 IgG 326 antibody response (Fenaux et al., 2003) . Herein in this study, we further demonstrated that 327 insertion of known PRRSV antigenic determinants in the C-terminus of PCV1 ORF2 capsid gene 328 produced infectious chimeric viruses and did not impair the humoral immune response against 329 PCV1. Although different levels of anti-PCV1 IgG were detected, all PCV1-VR2385 EPI chimeric 330 viruses were capable of induce anti-PCV1 IgG antibodies in infected SPF pigs. 331
The different levels of anti-PCV1 IgG antibodies might be associated with a different 332 replication timeline and viral DNA load observed amongst the various PCV1-VR2385 EPI 333 chimeric viruses compared with wild-type PCV1. The extension of the C-terminus of the PCV1 334 capsid gene through the addition of PRRSV antigenic epitopes might also affect the structural 335 conformation and antibody induction capability of the PCV1 capsid. Indeed, previous studies 336 demonstrated that mutation of the last four amino acid residues of the PCV2 ORF2 (-PLKP) to 337 three amino acid residues of the PCV1 ORF2 (-LNK) reduces viral antibody recognition 338 (Lekcharoensuk et al., 2004) . Therefore, in the current study, anti-PCV1 IgG antibodies 339 generated against PCV1-VR2385 EPI chimeric viruses may not completely bind to the full PCV1 340
Cap expressed by the wild-type PCV1 that was used for the IIFA serology test. Further studies 341 16 will be necessary to demonstrate whether the insertion of a foreign amino acid sequence at the C-342 terminus may alter the conformation of the PCV1 capsid protein. 343 It has been previously demonstrated that the C-terminus of the PCV2 capsid is a type-344 specific immune reactive epitope that is displayed on the surface of the virion capsid 345 (Lekcharoensuk et al., 2004; Shang et al., 2009) . In two separate studies, following the insertion 346 of epitope tags in the C-terminal region, PCV2 and chimeric PCV1-2a vaccine were generated 347 and shown to elicit dual immunity against both PCV2 capsid and the inserted epitopes, whereas 348 mutation of the N-terminus of PCV2 capsid impaired viral replication (Beach et al., 2011; 349 Pineyro et al., 2015) . Herein in the present study, we inserted four different known PRRSV 350 antigenic epitopes into the C-terminus of the non-pathogenic PCV1 capsid gene, and 351 demonstrated that the insertions did not significantly affect virus infectivity in vitro or viral 352 replication in vivo. We previously showed that epitopes as large as 27 amino acids can be 353 inserted in the PCV2 capsid gene without impairing viral viability (Beach et al., 2011) . In the 354 present study, we demonstrated that insertions, varying from 12 aa for PRRSV-GP3 epitope I 355 and PRRSV-GP5 epitope I, 12 aa for PRRSV-GP2 epitope II, and 14 aa for PRRSV-GP5 epitope 356 IV, did not affect viral infectivity in vitro or replication in vivo. Future study is necessary to 357 determine the tolerance of maximal length of amino acid insertion in PCV1 capsid without 358 affecting the viability of the virus. 359
Although the PCV1 chimeric viruses generated in this study were capable of replicating 360 in vivo, the rate of replication appears to be low. It has previously been demonstrated that PCV1 361 can replicate to a higher titer in vitro, compared to PCV2 (Beach et al., 2010a) . However, to our 362 knowledge, there is no information regarding the minimal infectious dose required for PCV1 363 infection in vivo. Previous studies using PCV1-2 chimeric virus in the backbone of PCV1 364
showed positive results with variable titers (Beach et al., 2010b; Fenaux et al., 2004; Pineyro et 365 al., 2015) . We therefore speculate that the low replication rate of the chimeric viruses observed 366 in this study might be due to a low virus titer that was used for inoculation. Propagation of 367 PCV1, PCV2 as well as chimeric viruses to higher infectious titers have been very challenging 368 thus far. 369
In the current study, PCV1 chimeric viruses expressing four known B-cell linear epitopes 370 of PRRSV, previously demonstrated to be immunogenic against PRRSV (de Lima et al., 2006; 371 Plagemann, 2004b; Vanhee et al., 2011) , were generated. It has been reported that GP5 plays a 372 major role in PRRSV neutralization (Plagemann, 2004a; Plagemann, 2004b; Plagemann et al., 373 2002) . PRRSV-GP5 epitope IV is an important immunogenic epitope (P 188 LTR (V/T) 374 SAEQW 197 ) that has also been proved to be reactive with sera raised against European PRRSV 375 strains. Despite a few amino acid changes, this epitope seems to be well conserved amongst type 376 2 PRRSV strains (Oleksiewicz et al., 2001) . We showed in this study that PCV1-377 VR2385 EPI GP5IV chimeric virus induced neutralizing antibody levels comparable to those 378 induced by the PRRSV VR2385 virus. The PRRSV-GP5 epitope I neutralizing epitope, 379 37 SHLQLIYNL, for the PRRSV VR2332 is located in the GP5 ectodomain sequence and is 380 considered as the primary neutralizing epitope for the type 2 PRRSV isolates (Plagemann, 381 2004b) . The PCV1-VR2385 EPI GP5I chimeric virus in this study induced similar neutralizing 382 antibody levels compared to those induced by PRRSV VR2385 virus at 28, and 35 dpi. However, 383 the neutralizing antibody titers induced by the PCV1-PRRSV EPI viruses appeared to decline more 384 rapidly compared to the PRRSV VR2385, thus causing a significant reduction of neutralizing 385 antibodies titer at 42 dpi. 386 PRRSV ORF3 is considered as the second most variable PRRSV structural protein, with 387 four consecutive peptides from aa 61-105, all of which are considered as important 388 immunodominant domains of GP3 (de Lima et al., 2006; Zhou et al., 2006) . The PCV1-389 VR2385 EPI GP3I chimeric virus generated in this study contains the aa 61-72 390 (QAAAEAYEPGRS) and was shown to induce similar levels of neutralizing antibodies 391 compared to the PRRSV VR2385. Despite the fact that PCV1-VR2385EPIGP2II chimeric virus 392 is infectious in vitro, no viral DNA were detected in tissues of inoculated pigs, probably due to 393 the short duration of viremia not being detectable with the current sampling scheme. This 394 explanation was also supported by the presence of anti-PCV1 IgG at 14 dpi, indicative of virus 395 replication. Furthermore, the chimeric virus also failed to induce antibodies against PRRSV-GP2 396 epitope II. Therefore, we have successfully demonstrated that three of the four PCV1-VR2385 EPI 397 chimeric viruses generated in this study induced PRRSV epitope-specific antibodies and 398 neutralizing antibodies against PRRSV VR2385 at a level comparable to those induced by wild-399 type PRRSV VR2385. 400
In summary, we successfully generated and rescued four PCV1 chimeric viruses 401 expressing different known PRRSV linear-B epitopes (GP2 epitope II: aa 40-51, 402 ASPSHVGWWSFA; GP3 epitope I: aa 61-72, QAAAEAYEPGRS; GP5 epitope I: aa 35-46, 403 SSSNLQLIYNLT; and GP5 epitope IV: aa 187-200, TPVTRVSAEQWGRP). We further 404
showed that three of these chimeric viruses were infectious in vitro and in pigs, and genetically 405 stable. Importantly, we found that three PCV1-VR2385 EPI chimeric viruses elicited neutralizing 406 antibodies against PRRSV-VR2385. Therefore, the results from the present study provided a 407 proof of concept for further exploring the use of the non-pathogenic PCV1 as a live virus vector 408 for vaccine delivery. 409 The first amplicon of 200 bp containing an overhanging GPxx EPI region (xx denote different 571 inserted epitopes, GP2II, G3I, GP5I and GP5IV) was generated with M13-F and GPxx EPI -R 572 primers (black arrows). The second amplicon of 1778 bp containing a complementary GPxx EPI 573 overhanging region was generated with GPxx EPI -F and M13-R primers (empty arrow heads). The 574 full-length PCV1-PRRSV epitopes chimeric clones were assembled by a fusion PCR using 575 previously generated amplicons as templates, and with M13-F and M13-R primers. 576 577
Fig. 2. Confocal microscopy of PK-15 cells infected with wild-type PCV1 as well as with 578
four different PCV1-PRRSV EPI chimeric viruses. PCV1-PRRSV EPI chimeric viruses (PCV1-579 VR2385 EPI GP2II, PCV1-VR2385 EPI GP3I, PCV1-VR2385 EPI GP5I, and PCV1-VR2385 EPI GP5IV) 580 and wild-type PCV1 were assayed by dual immunofluorescence staining. Infected cells were 581 dually labeled with a mixture of mouse anti-PCV1 capsid monoclonal antibody (1:1000) (Mab) 582 and PRRSV epitope-specific polyclonal antibodies (1:500) (Pab). In order to determine cross 583 reactivity, cells infected with each specific chimeric virus group were tested against each 584 respective PRRSV-specific epitope antibody. After incubation with the primary antibody, a 585 mixture of fluorescein isothiocyanate (FITC) conjugated goat anti-mouse IgG (1:100) (KPL, 586
Kirkegaard & Perry Laboratories, Inc.) and goat anti-rabbit IgG-DyLight (1:500) (Thermo 587 Scientific) were added. Dually infected cells were visualized using a Zeiss LSM 880 confocal 588 microscope (Zeiss, Pleasanton, CA) with a 40X objective, using the argon 488 and helium-neon 589 594 lasers. 590 
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